Zobrazeno 1 - 10
of 929
pro vyhledávání: ''
Autor:
Vanathi Sivasubramaniam, Michael Boyer, Rina Hui, Jia Liu, Prunella Blinman, Jenny H. Lee, Nick Pavlakis, Stephen Clarke, Anthony J. Gill, Steven Kao, Winny Varikatt, Wendy A Cooper, Malinda Itchins, Megan B Barnet, Madhawa De Silva, Bo Gao, Alexander E. Davis, Adnan Nagrial, Kenneth Lee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 155
Predictive biomarkers for poor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an area of ongoing research. This multicentre retrospective study sought to determine the impact of programmed death-ligand 1 (PD-
Autor:
Hidetoshi Kasuya, Bierta E. Barfod, Toru Serizawa, Yasunori Sato, Masaaki Yamamoto, Yoshinori Higuchi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 149
There is little information on stereotactic radiosurgery (SRS) results for brain metastases (BMs) in lung cancer patients ≥75 years of age. We aimed to reappraise whether SRS results for patients ≥75 (very elderly) differ from those of patients w
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Several obstacles may delay receipt of targeted treatment in patients with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC). This study examined the factors associated with delayed initiation of ALK inhibitor
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du
Autor:
José Hureaux, Christos Chouaid, Anne Marie Chiappa, Mateo Sanchis-Borja, Isabelle Monnet, Jean-Bernard Auliac, Renaud Descourt, Luc Odier, Radj Gervais, Charles Ricordel, Gaelle Jeannin
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Using immune-checkpoint inhibitors (ICIs) to manage cancer is associated with various immune-related adverse events. Central and/or peripheral neurological disorders are rare and potentially serious. We analyzed the characteristics of no
Autor:
Masato Karayama, Satoshi Goshima, Nobuko Yoshizawa, Hideki Yasui, Hironao Hozumi, Naoki Inui, Yutaro Nakamura, Kazuki Furuhashi, Yasuo Takehara, Takafumi Suda, Tomoyuki Fujisawa, Masataka Sugiyama, Kazutaka Mori, Yuzo Suzuki, Noriyuki Enomoto
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Objectives Conventional evaluation of anti-tumor activity on the basis of tumor size is inadequate for immune checkpoint inhibitors (ICIs). We therefore aimed to assess the usefulness of intravoxel incoherent motion magnetic resonance imaging (IVIM-M
Autor:
Matteo Giaj Levra, V. Grumberg, Anne-Françoise Gaudin, John R. Penrod, Jean-Baptiste Assié, Christos Chouaid, François-Emery Cotté, Ronan Jolivel, B. Jouaneton, C. Calvet, Romain Corre
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 140
Objectives Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolum
Autor:
Kaiyan Chen, Xiaoqing Yu, Zhiyu Huang, Yun Fan, Guoping Cheng, Yanjun Xu, Fanrong Zhang, Guanxia Zhu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade
Autor:
Michael Millward, Stephen Clarke, Adrian Lee, Benjamin Solomon, Steven Kao, Malinda Itchins, Thomas John, Kate Burbury, Sarah A. Hayes, Brett G.M. Hughes, Nick Pavlakis, Viive M. Howell, Marliese Alexander, Rachel O'Connell
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
Objectives: This study aimed to describe the longitudinal thromboembolism (TE) risk relative to the natural history of disease and clinical course of ROS1 rearranged non-small cell lung cancer (NSCLC). Materials and Methods Cases of ROS1-rearranged N
Autor:
Hojoong Kim, Byung Woo Jhun, Jungho Han, Sun Hye Shin, Hongseok Yoo, Sang-Won Um, Jhingook Kim, O Jung Kwon, Kyungjong Lee, Kyung Soo Lee, Byeong-Ho Jeong
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Objectives Recent practice guidelines recommend endosonography for patients with radiological N0 non-small cell lung cancer (NSCLC) when the primary tumors are >3 cm in diameter or centrally located. However, any role for endosonography remains debat